Previous close | 75.03 |
Open | 75.00 |
Bid | 75.13 x 500 |
Ask | 75.18 x 500 |
Day's range | 74.59 - 75.49 |
52-week range | 60.47 - 75.81 |
Volume | |
Avg. volume | 6,389,106 |
Market cap | 233.06B |
Beta (5Y monthly) | 0.19 |
PE ratio (TTM) | 37.21 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.45 (1.93%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced the acceptance of an abstract related to the clinical study of C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T-Cell (CAR-T) therapy, in hepatocellular carcinoma (HCC) for oral presentation at the American Society of Clinical Oncology (ASCO) Annual M
CAMBRIDGE, United Kingdom, April 25, 2024--Q1 Earnings Release (25 April 2024)
WILMINGTON, Del., April 16, 2024--Updated exploratory results from the TOPAZ-1 Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) in combination with standard-of-care chemotherapy demonstrated a clinically meaningful long-term overall survival (OS) benefit at three years for patients with advanced biliary tract cancer (BTC).